Semaglutide, a GLP1-RA offered in subcutaneous and oral formulations, holds promise as a treatment for NAFLD due to its multifaceted mechanisms of action, rendering it a promising treatment for the disease [28]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.